BioSpace News Archive

New Data Presented at ASCO Genitourinary Cancers Symposium Finds Adding PROVENGE to Commonly Prescribed Oral Therapies Extends Median Survival by 14.5 Months

Luminex Corporation announced that Homi Shamir, President & CEO, and Harriss Currie, Senior Vice President of Finance and CFO, plan to participate at three investor conferences in March 2020.

Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ® (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its audited 2019 fourth quarter and full-year financial results and provide a corporate update on February 20, 2020.

Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed definitive agreement (“Agreement”) with Collegium Pharmaceutical, Inc. (“Collegium”), pursuant to which Collegium has acquired the NUCYNTA® franchise of products from the Company.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Alex C. Sapir to its board of directors.

Urovant Sciences (Nasdaq: UROV) today reported financial results for the 2019 third fiscal quarter ended December 31, 2019.

Seelos Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share.

Beyond Type 1, a global diabetes nonprofit, announced the launch of websites in Dutch, French, German, Italian, and Swedish.

Feb. 13, 2020 17:00 UTC Trial focuses on symptom endpoints for seropositive patients NEWPORT BEACH, Calif.--( BUSINESS WIRE )-- ImmunogenX is pleased to announce that patient enrollment has begun for a Phase 2b clinical trial (NCT04243551, named “Solutions for Celiac”™). This trial is funded by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) as a grant to ImmunogenX. The multi-center trial includes Columbia University